JP2002503495A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002503495A5 JP2002503495A5 JP2000532092A JP2000532092A JP2002503495A5 JP 2002503495 A5 JP2002503495 A5 JP 2002503495A5 JP 2000532092 A JP2000532092 A JP 2000532092A JP 2000532092 A JP2000532092 A JP 2000532092A JP 2002503495 A5 JP2002503495 A5 JP 2002503495A5
- Authority
- JP
- Japan
- Prior art keywords
- humanized antibody
- seq
- variable region
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 2
Description
【請求項９】 請求項７に記載の核酸分子を含む発現ベクター。
【請求項１０】 請求項８に記載の核酸分子を含む発現ベクター。
【請求項２１】 配列番号８に示す軽鎖可変領域アミノ酸配列を含む、請求項１１に記載のヒト化抗体。
【請求項２２】 配列番号１０に示す重鎖可変領域アミノ酸配列を含む、請求項１１に記載のヒト化抗体。
【請求項２３】 配列番号８に示す軽鎖可変領域アミノ酸配列を含む、請求項１２に記載のヒト化抗体。
【請求項２４】 配列番号１０に示す重鎖可変領域アミノ酸配列を含む、請求項１２に記載のヒト化抗体。
【請求項２５】 配列番号８に示す軽鎖可変領域アミノ酸配列および配列番号１０に示す重鎖可変領域アミノ酸配列を含む、請求項１１に記載のヒト化抗体。
【請求項２６】 配列番号１２に示す軽鎖可変領域アミノ酸配列を含む、請求項１１に記載のヒト化抗体。
【請求項２７】 配列番号１０に示す重鎖可変領域アミノ酸配列を含む、請求項２６に記載のヒト化抗体。
【請求項２８】 配列番号１２に示す軽鎖可変領域アミノ酸配列および配列番号１０に示す重鎖可変領域アミノ酸配列を含む、請求項１１に記載のヒト化抗体。
本発明のキメラ抗体（キメラ抗体２.２２０）の好ましい軽鎖をコードする核酸は、アメリカン・タイプ・カルチャー・コレクションに寄託してあり、ＡＴＣＣ２０３６３０の受託番号を付与されている。本発明のキメラ抗体（キメラ抗体２.２２０）の好ましい重鎖をコードする核酸は、アメリカン・タイプ・カルチャー・コレクションに寄託してあり、ＡＴＣＣ２０３６２９の受託番号を付与されている。
本発明のヒト化抗体（ヒト化抗体Ｆ４）の好ましい軽鎖をコードする核酸は、アメリカン・タイプ・カルチャー・コレクションに寄託してあり、ＡＴＣＣ２０３６２８の受託番号を付与されている。本発明のヒト化抗体（ヒト化抗体Ｌ３.１７）のさらに好ましい軽鎖をコードする核酸は、アメリカン・タイプ・カルチャー・コレクションに寄託してあり、ＡＴＣＣ２０３７７４の受託番号を付与されている。本発明のヒト化抗体（Ｆ４およびＬ３.１７）の好ましい重鎖をコードする核酸は、アメリカン・タイプ・カルチャー・コレクションに寄託してあり、ＡＴＣＣ２０３６３１の受託番号を付与されている。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/026,291 | 1998-02-19 | ||
| US09/026,291 US6051228A (en) | 1998-02-19 | 1998-02-19 | Antibodies against human CD40 |
| PCT/US1999/002949 WO1999042075A2 (en) | 1998-02-19 | 1999-02-10 | Antibodies against human cd40 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002503495A JP2002503495A (ja) | 2002-02-05 |
| JP2002503495A5 true JP2002503495A5 (ja) | 2006-03-23 |
Family
ID=21830976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000532092A Withdrawn JP2002503495A (ja) | 1998-02-19 | 1999-02-10 | ヒトｃｄ４０に対する抗体 |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US6051228A (ja) |
| EP (1) | EP1054692A4 (ja) |
| JP (1) | JP2002503495A (ja) |
| KR (1) | KR100564376B1 (ja) |
| CN (1) | CN1198647C (ja) |
| AR (1) | AR018101A1 (ja) |
| AU (1) | AU751064B2 (ja) |
| BG (1) | BG65010B1 (ja) |
| BR (1) | BR9908045A (ja) |
| CA (1) | CA2321165A1 (ja) |
| CO (1) | CO4830493A1 (ja) |
| CZ (1) | CZ20003008A3 (ja) |
| EE (1) | EE200000470A (ja) |
| GE (1) | GEP20033016B (ja) |
| HU (1) | HUP0100763A3 (ja) |
| ID (1) | ID25792A (ja) |
| IL (2) | IL137294A0 (ja) |
| LT (1) | LT4837B (ja) |
| LV (1) | LV12561B (ja) |
| MY (1) | MY121464A (ja) |
| NO (1) | NO20004133L (ja) |
| NZ (1) | NZ505696A (ja) |
| PE (1) | PE20000268A1 (ja) |
| PL (1) | PL197143B1 (ja) |
| RU (1) | RU2220980C2 (ja) |
| SK (1) | SK12092000A3 (ja) |
| TR (1) | TR200002405T2 (ja) |
| TW (1) | TWI226334B (ja) |
| UA (1) | UA71909C2 (ja) |
| WO (1) | WO1999042075A2 (ja) |
| ZA (1) | ZA991307B (ja) |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US7175847B1 (en) * | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
| US7153508B2 (en) * | 1995-06-07 | 2006-12-26 | Biogen Idec Inc. | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 |
| US6113898A (en) * | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| JP4219985B2 (ja) * | 1996-07-23 | 2009-02-04 | タノックス ファーマ ベスローテン フェンノートシャップ | 二つの共刺激経路を同時にブロックできる可溶性分子を用いたｔ細胞寛容の誘導 |
| US6051228A (en) * | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| EP1181050A4 (en) | 1999-04-30 | 2005-05-18 | Jolla Inst Allergy Immunolog | METHODS FOR PREVENTING THE REACTIVATION OF LATENT VIRUSES AND CONTROLLING VIRUS REPLICATION |
| DK1176981T3 (da) | 1999-05-07 | 2006-04-10 | Genentech Inc | Behandling af autoimmune sygdomme med antagonister som binder til B celleoverflademarkörer |
| US7829064B2 (en) * | 1999-05-10 | 2010-11-09 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods |
| US8119101B2 (en) * | 1999-05-10 | 2012-02-21 | The Ohio State University | Anti-CD74 immunoconjugates and methods of use |
| US8383081B2 (en) * | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
| US6946129B1 (en) * | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| EP1194167B1 (en) * | 1999-06-09 | 2009-08-19 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| WO2001013945A1 (en) * | 1999-08-23 | 2001-03-01 | Biocrystal Ltd. | Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis |
| EP1839674A1 (en) * | 1999-10-04 | 2007-10-03 | Novartis Vaccines and Diagnostics, Inc. | CD40 antagonist for treating psoriasis |
| EP1221973B1 (en) * | 1999-10-04 | 2007-05-30 | Novartis Vaccines and Diagnostics, Inc. | CD40 antagonist for treating psoriasis |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| WO2001034649A2 (en) * | 1999-11-09 | 2001-05-17 | Chiron Corporation | Compositions and methods for treating autoimmune diseases and transplant rejections |
| GB0001448D0 (en) | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
| GB0006398D0 (en) * | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| CN1450912A (zh) * | 2000-04-19 | 2003-10-22 | 泰诺士公司 | 用于治疗牛皮癣和其它炎性皮肤病的cd40拮抗剂 |
| US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| MXPA03002262A (es) * | 2000-09-18 | 2003-10-15 | Idec Pharma Corp | Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b. |
| IL157946A0 (en) * | 2001-04-02 | 2004-03-28 | Genentech Inc | Combination therapy |
| CA2658221C (en) * | 2001-04-27 | 2012-11-27 | Kyowa Hakko Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
| US20030091593A1 (en) * | 2001-09-14 | 2003-05-15 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| EP1455812A4 (en) * | 2001-11-26 | 2006-03-22 | Chiron Corp | TREATMENT OF ANTI-CD40 MONOCLONAL ANTIBODY FOR THE TREATMENT OF MULTIPLE SCLEROSIS |
| EP2075256A2 (en) | 2002-01-14 | 2009-07-01 | William Herman | Multispecific binding molecules |
| EP2308898B1 (en) * | 2002-03-01 | 2016-06-08 | Immunomedics, Inc. | Internalizing anti-CD74 antibodies and methods of use |
| US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| AU2003300842A1 (en) * | 2002-12-09 | 2004-06-30 | Tolerrx, Inc. | Inducing tolerance in primates |
| US8420086B2 (en) | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| PT1682178E (pt) * | 2003-11-04 | 2010-10-21 | Novartis Vaccines & Diagnostic | Métodos de terapêutica para cancros que expressam o antigénio cd40 |
| US7312320B2 (en) * | 2003-12-10 | 2007-12-25 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
| US7674884B2 (en) * | 2003-12-10 | 2010-03-09 | Novimmune S.A. | Neutralizing antibodies and methods of use thereof |
| US8883160B2 (en) * | 2004-02-13 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
| US9550838B2 (en) | 2004-02-13 | 2017-01-24 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
| AU2005227322A1 (en) | 2004-03-23 | 2005-10-06 | Biogen Idec Ma Inc. | Receptor coupling agents and therapeutic uses thereof |
| AU2004324464A1 (en) * | 2004-10-22 | 2006-05-04 | Applied Molecular Evolution, Inc. | Methods of optimizing antibody variable region binding affinity |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
| US8349332B2 (en) | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
| US8475794B2 (en) | 2005-04-06 | 2013-07-02 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases |
| CN101198347A (zh) * | 2005-04-06 | 2008-06-11 | 布里斯托尔-迈尔斯斯奎布公司 | 使用可溶性ctla4突变型分子治疗与移植物移植有关的免疫病症的方法 |
| PL1889065T3 (pl) * | 2005-05-18 | 2013-12-31 | Novartis Ag | Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny |
| CA2609269C (en) * | 2005-05-26 | 2014-08-05 | Seattle Genetics, Inc. | Humanized anti-cd40 antibodies and their methods of use |
| US7668387B2 (en) * | 2005-06-20 | 2010-02-23 | Intel Corporation | Selective local transient improvement and peaking for video sharpness enhancement |
| PT2298815E (pt) * | 2005-07-25 | 2015-07-16 | Emergent Product Dev Seattle | Moléculas de ligaçao especificas para cd37 e especificas para cd20 |
| WO2007033369A2 (en) * | 2005-09-14 | 2007-03-22 | University Of Pittsburgh | Assessing risk of cerebrovascular thrombosis by measuring c4d on platelets |
| US20080131914A1 (en) * | 2005-09-14 | 2008-06-05 | Ahearn Joseph M | Assessing risk of cerebrovascular thrombosis by measuring c4d |
| US20070202549A1 (en) * | 2005-09-14 | 2007-08-30 | University Of Pittsburgh | Assessing risk of cerebrovascular thrombosis by measuring C4d on platelets |
| KR20080073725A (ko) | 2005-11-01 | 2008-08-11 | 노파르티스 아게 | 항-ｃｄ40 항체의 용도 |
| WO2007124299A2 (en) | 2006-04-21 | 2007-11-01 | Novartis Ag | Antagonist anti-cd40 antibody pharmaceutical compositions |
| US7993648B2 (en) * | 2006-05-03 | 2011-08-09 | The Regents of the Universitry of Colorado | Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody |
| EP1854810A1 (en) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
| US7964574B2 (en) * | 2006-08-04 | 2011-06-21 | Baxter International Inc. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
| US20090074711A1 (en) * | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
| DK2474557T3 (da) | 2007-07-16 | 2014-11-10 | Genentech Inc | Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse |
| WO2009012256A1 (en) | 2007-07-16 | 2009-01-22 | Genentech, Inc. | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
| DK2657253T3 (en) | 2008-01-31 | 2017-10-09 | Genentech Inc | Anti-CD79b antibodies and immune conjugates and methods of use |
| WO2010104747A2 (en) | 2009-03-10 | 2010-09-16 | Baylor Research Institute | Antigen presenting cell targeted vaccines |
| MX2011009439A (es) * | 2009-03-10 | 2013-06-18 | Baylor Res Inst | Vacunas con especificidad de objetivo hacia celula presentadora de antigeno. |
| WO2011085354A1 (en) * | 2010-01-11 | 2011-07-14 | Center For Molecular Medicine And Immunology | Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma |
| EP3178851B1 (en) | 2010-03-31 | 2020-04-29 | Boehringer Ingelheim International GmbH | Anti-cd40 antibodies |
| PT2569013T (pt) * | 2010-05-14 | 2017-02-08 | Univ Leland Stanford Junior | Anticorpos monoclonais humanizados e quiméricos para cd47 |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| HUE044591T2 (hu) | 2011-03-11 | 2019-11-28 | Beth Israel Deaconess Medical Ct Inc | Anti-CD40 antitestek és alkalmazásuk |
| DK2699601T3 (en) | 2011-04-21 | 2018-04-23 | Bristol Myers Squibb Co | ANTIBODY POLYPEPTIDES ANTAGONIZING CD40 |
| JP6125489B2 (ja) | 2011-04-29 | 2017-05-10 | アペクシジェン， インコーポレイテッド | 抗ｃｄ４０抗体および使用方法 |
| GB201115280D0 (en) | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| BR112014009069A2 (pt) | 2011-10-13 | 2020-10-27 | Bristol-Myers Squibb Company | polipeptídeos de anticorpo que antagonizam cd40l |
| EP2788020A4 (en) | 2011-12-05 | 2015-04-29 | Immunomedics Inc | THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR THE INDUCTION OF TROGO CYTOSIS |
| US9757458B2 (en) | 2011-12-05 | 2017-09-12 | Immunomedics, Inc. | Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells |
| AU2013337903B2 (en) | 2012-10-30 | 2018-08-16 | Apexigen, Inc. | Anti-CD40 antibodies and methods of use |
| WO2015012904A2 (en) | 2012-12-13 | 2015-01-29 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
| PL2900277T3 (pl) | 2012-12-13 | 2022-05-16 | Immunomedics, Inc. | Dawkowanie immunokoniugatów przeciwciał i sn-38 dla poprawy skuteczności i zmniejszenia toksyczności |
| US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
| US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
| US10206918B2 (en) | 2012-12-13 | 2019-02-19 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
| US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| US10744129B2 (en) | 2012-12-13 | 2020-08-18 | Immunomedics, Inc. | Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 |
| US10413539B2 (en) | 2012-12-13 | 2019-09-17 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
| US11253606B2 (en) | 2013-07-23 | 2022-02-22 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| US10286058B2 (en) | 2014-01-13 | 2019-05-14 | Baylor Research Institute | Vaccines against HPV and HPV-related diseases |
| WO2015130416A1 (en) | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| EP3113796A1 (en) | 2014-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
| DK3180087T3 (da) | 2014-08-12 | 2019-05-13 | Alligator Bioscience Ab | Kombinationsterapier med anti cd40-antistoffer |
| SG11201702056YA (en) * | 2014-09-16 | 2017-04-27 | United Biomedical Inc | Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition |
| PT3262071T (pt) | 2014-09-23 | 2020-06-16 | H Hoffnabb La Roche Ag | Métodos de utilização de imunoconjugados anti-cd79b |
| WO2016069919A1 (en) | 2014-10-29 | 2016-05-06 | Seattle Genetics, Inc. | Dosage and administration of non-fucosylated anti-cd40 antibodies |
| KR102656470B1 (ko) | 2014-12-10 | 2024-04-09 | 리전츠 오브 더 유니버스티 오브 미네소타 | 질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기 |
| JP6746845B2 (ja) | 2015-04-22 | 2020-08-26 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 循環ｔｒｏｐ−２陽性癌細胞の単離、検出、診断及び／または特徴付け |
| SI3303395T1 (sl) | 2015-05-29 | 2020-03-31 | Abbvie Inc. | Protitelesa proti CD40 in njihove uporabe |
| US10195175B2 (en) | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
| SI3307322T1 (sl) | 2015-09-04 | 2021-08-31 | Primatope Therapeutics Inc. | Humanizirana protitelesa proti CD40 in njihove uporabe |
| BR112018006360A2 (pt) | 2015-09-30 | 2018-10-09 | Janssen Biotech Inc | anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso |
| CN108601841A (zh) | 2016-02-10 | 2018-09-28 | 免疫医疗公司 | Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性 |
| JP7208492B2 (ja) | 2016-03-10 | 2023-01-19 | シージー オンコロジー， インコーポレイテッド | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
| EP3448260A4 (en) | 2016-04-27 | 2019-10-09 | Immunomedics, Inc. | EFFICACY OF ANTI-TROP-2 SN-38 ANTIBODY CONJUGATES FOR THE THERAPY OF REZIDIVATED / REFRACTORY TUMORS AGAINST CHECKPOINT INHIBITORS |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| EP3600283A4 (en) | 2017-03-27 | 2020-12-16 | Immunomedics, Inc. | TREATMENT OF TROP-2 EXPRESSIVE TRIPLE NEGATIVE BREAST CANCER WITH SACITUZUMAB GOVITECAN AND A RAD51 INHIBITOR |
| WO2018187074A1 (en) | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
| CA3105875A1 (en) * | 2018-07-20 | 2020-01-23 | Eucure (Beijing) Biopharma Co., Ltd | Anti-cd40 antibodies and uses thereof |
| US20200190163A1 (en) * | 2018-10-26 | 2020-06-18 | Lijun Wu | Humanized bcma-car-t cells |
| CN113166246A (zh) * | 2018-12-28 | 2021-07-23 | 四川科伦博泰生物医药股份有限公司 | 一种抗体及其用途 |
| CN111454363B (zh) * | 2019-03-04 | 2021-03-02 | 北京天广实生物技术股份有限公司 | Cd40抗体及其用途 |
| JP2022547850A (ja) * | 2019-09-03 | 2022-11-16 | バイオ － テラ ソリューションズ、リミテッド | 抗ｔｉｇｉｔ免疫阻害剤及び応用 |
| CN113563473A (zh) | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| CN111763259B (zh) * | 2020-09-03 | 2020-12-15 | 北京百奥赛图基因生物技术有限公司 | 抗cd40抗体及其用途 |
| CN117500816A (zh) | 2021-08-26 | 2024-02-02 | 映恩生物制药（苏州）有限公司 | 一种甾体化合物及其缀合物 |
| CN118234749A (zh) * | 2021-09-17 | 2024-06-21 | 诺华股份有限公司 | 用于预防异种移植中的移植物排斥的方法 |
| US20240190978A1 (en) | 2022-11-15 | 2024-06-13 | CSBioAsset LLC | Compositions and methods for immunomodulatory bifunctional fusion molecules |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1993011252A1 (en) * | 1991-11-26 | 1993-06-10 | The Regents Of The University Of California | Cloning vectors for expressing pcr generated variable regions as complete heavy and/or light chain(s) |
| US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US5874082A (en) * | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| JP2911056B2 (ja) * | 1995-04-08 | 1999-06-23 | 株式会社エルジ化学 | ヒト４−１ｂｂに特異的なモノクローナル抗体およびこれを産生する細胞株 |
| US6051228A (en) * | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| KR20000034847A (ko) * | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
-
1998
- 1998-02-19 US US09/026,291 patent/US6051228A/en not_active Expired - Lifetime
-
1999
- 1999-01-30 MY MYPI99000336A patent/MY121464A/en unknown
- 1999-02-10 GE GEAP19995505A patent/GEP20033016B/en unknown
- 1999-02-10 IL IL13729499A patent/IL137294A0/xx active IP Right Grant
- 1999-02-10 AU AU26716/99A patent/AU751064B2/en not_active Ceased
- 1999-02-10 ID IDW20001577A patent/ID25792A/id unknown
- 1999-02-10 NZ NZ505696A patent/NZ505696A/en unknown
- 1999-02-10 CZ CZ20003008A patent/CZ20003008A3/cs unknown
- 1999-02-10 BR BR9908045-1A patent/BR9908045A/pt not_active Application Discontinuation
- 1999-02-10 KR KR1020007009046A patent/KR100564376B1/ko not_active IP Right Cessation
- 1999-02-10 CN CNB998031496A patent/CN1198647C/zh not_active Expired - Fee Related
- 1999-02-10 SK SK1209-2000A patent/SK12092000A3/sk unknown
- 1999-02-10 EE EEP200000470A patent/EE200000470A/xx unknown
- 1999-02-10 WO PCT/US1999/002949 patent/WO1999042075A2/en active IP Right Grant
- 1999-02-10 EP EP99906915A patent/EP1054692A4/en not_active Withdrawn
- 1999-02-10 HU HU0100763A patent/HUP0100763A3/hu unknown
- 1999-02-10 CA CA002321165A patent/CA2321165A1/en not_active Abandoned
- 1999-02-10 JP JP2000532092A patent/JP2002503495A/ja not_active Withdrawn
- 1999-02-10 TR TR2000/02405T patent/TR200002405T2/xx unknown
- 1999-02-10 RU RU2000124084/13A patent/RU2220980C2/ru not_active IP Right Cessation
- 1999-02-10 PL PL342668A patent/PL197143B1/pl unknown
- 1999-02-10 US US09/247,352 patent/US6312693B1/en not_active Expired - Lifetime
- 1999-02-18 ZA ZA9901307A patent/ZA991307B/xx unknown
- 1999-02-18 CO CO99010014A patent/CO4830493A1/es unknown
- 1999-02-19 PE PE1999000146A patent/PE20000268A1/es not_active Application Discontinuation
- 1999-02-22 TW TW088102330A patent/TWI226334B/zh not_active IP Right Cessation
- 1999-02-23 AR ARP990100704A patent/AR018101A1/es active IP Right Grant
- 1999-10-02 UA UA2000095347A patent/UA71909C2/uk unknown
- 1999-12-17 US US09/466,635 patent/US6413514B1/en not_active Expired - Lifetime
-
2000
- 2000-07-13 IL IL137294A patent/IL137294A/en unknown
- 2000-08-17 LT LT2000080A patent/LT4837B/lt not_active IP Right Cessation
- 2000-08-18 NO NO20004133A patent/NO20004133L/no not_active Application Discontinuation
- 2000-08-23 LV LVP-00-107A patent/LV12561B/en unknown
- 2000-09-19 BG BG104778A patent/BG65010B1/bg unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002503495A5 (ja) | ||
| JP2002524024A5 (ja) | ||
| JP2004531270A5 (ja) | ||
| JP2003522514A5 (ja) | ||
| EP2322552A3 (en) | IL-1beta binding antibodies and fragments thereof | |
| JP2003524587A5 (ja) | ||
| IN2009KN02655A (ja) | ||
| NZ503763A (en) | Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use | |
| HK1142272A1 (en) | Specific binding proteins and uses thereof | |
| WO2003070760A3 (en) | Anti-amyloid beta antibodies and their use | |
| EP1162206A3 (en) | Peptide nucleic acids | |
| RS50477B (sr) | Anti-il-12 antitela, kompozicije, metode i njihove upotrebe | |
| CA2477163A1 (en) | Soluble form of carbonic anhydrase ix (s-ca-ix), assays to detect s-ca ix, and ca ix's coexpression with her-2/neu/c-erbb-2, and ca ix-specific monoclonal antibodies to non-immunodominant epitopes | |
| EP1762619A3 (en) | Multiple-tumor aberrant growth genes | |
| JP2002535956A5 (ja) | ||
| RU2004115112A (ru) | Антитела человека, обладающие активностью связывания c mn и нейтрализации клеточной адгезии | |
| JP2004528803A5 (ja) | ||
| CA2457362A1 (en) | Human monoclonal rabies virus neutralizing antibodies, and methods for making and using the same | |
| CA2361987A1 (en) | Goodpasture antigen binding protein | |
| DE69737323D1 (de) | Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet | |
| RU2206610C2 (ru) | Выделенная и очищенная молекула нуклеиновой кислоты (варианты), плазмидный вектор, выделенный и очищенный высокомолекулярный белок (hmw) нетипичных haemophilus, конъюгат, синтетический пептид | |
| ITMI930456A1 (it) | Vettore ricombinante e suo impiego per la preparazione esocellulare di anticorpi in forma di singola molecola da bacillus subtilis | |
| NZ500151A (en) | A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence | |
| CA2441187A1 (en) | Acetyllysine-recognizing monoclonal antibody and process for producing the same | |
| WO2000018803A3 (en) | Antibodies to mammalian langerhans cell antigen and their uses |